GPCR · Structure Therapeutics Inc.

Track GPCR — free

$41.23 +0.85 (+2.11%) At close · Sep 9

Rebalance outlook locked

Market Cap

$3.17B

71.31M

Up next

Latest filing: 10-Q

filed Aug 6, 2026

Metrics snapshot

Useful current figures from the complete screener profile.

View all 115 metrics

Revenue (TTM)

—

Trailing 12 months

Net income (TTM)

−$214.84M

Trailing 12 months

Revenue growth YoY

—

Year over year

Operating margin

—

Trailing 12 months

P / E (TTM)

—

Trailing earnings

FCF yield

—

TTM · current market cap

Return on invested capital

—

Trailing 12 months

Net cash

$1.34B

Latest balance sheet

Dividend yield

—

Trailing 12 months

Shares change YoY

+26.2%

Year over year · more shares

Price change (1Y)

+93.6%

Trailing year

Short interest

8.5%

Latest settlement · 10.4 days to cover

View all 115 metrics

Equibles Rating

blended score · not investment advice

Overall

Strong Sell

SellHoldBuy

Technical Sell Momentum Very Weak Sentiment Bearish Fundamentals Poor Quant / Vol Very High

Market backdrop VIX 15.7 · calm Equity put/call 0.48

Technical

price trend

Sell

50 / 200-day cross No cross

Price vs 200-day avg −24%

below

Price vs 50-day avg −18%

below

RSI (14) 30

neutral

MACD trend Negative

52-week position 29%

mid-range

Volume (OBV) Confirms

volume backs price

Momentum

relative strength

Very Weak

1-month return −21%

trailing

6-month return −21%

trailing

YTD return −41%

this year

Relative strength −36%

vs S&P · 6-mo

Sentiment

smart money

Bearish

Trend (MA cross) No cross

50d $50 › 200d $54 — 200d above 50d

Institutional flow Distributing

-3% holders QoQ · +28 funds added

Insider flow Flat

No net insider activity over 90 days

Short interest Rising

8.53% of float · ▲ +0.5% MoM · 10.4 days cover

Volume signal Normal

Volume near normal

Institution breadth Steady

193 holders — mid 3-yr range

Squeeze score 55

elevated · 0–100

Fundamentals

Poor

EPS growth −3%

Y/Y

Free cash flow $-225.8M

Quant / Vol

risk profile

Very High

Volatility 119%

annualized · 1-yr

Max drawdown −62%

past year

ATR 6.7%

of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Sell

3 · 4 · 0

50 / 200-day cross

No cross Neutral

Price vs 200-day avg

−24% Bearish

Price vs 50-day avg

−18% Bearish

RSI (14)

30 Neutral

MACD trend

Negative Bearish

52-week position

29% Neutral

Volume (OBV)

Confirms Neutral

Market signals — smart money & positioning

Bearish · 2 of 6

Trend (MA cross) No cross

50d $50 › 200d $54 — 200d above 50d

Institutional flow Distributing

-3% holders QoQ · +28 funds added

Insider flow Flat

No net insider activity over 90 days

Short interest Rising

8.53% of float · ▲ +0.5% MoM · 10.4 days cover

Volume signal Normal

Volume near normal

Institution breadth Steady

193 holders — mid 3-yr range

Price context

position in its 52-week range

Range low $20 Now $41 · 29% Range high $94

vs 200-day avg -24% vs 50-day avg -18%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.

Versus peers

Biotechnology — same industry group

Open screener →

Company	Mkt cap	YTD	Rev growth Y/Y	P/E	Short % shares
GPCR Structure Therapeutics Inc. this stock	$3.17B	-40.7%	—	—	8.5%
VRTX Vertex Pharmaceuticals Inc / Ma	$132.08B	+14.9%	+46.2%	30.4	1.6%
REGN Regeneron Pharmaceuticals, Inc.	$83.15B	+4.6%	+20.8%	20.0	2.3%
ARGX Argenx SE	$62.63B	+19.2%	—	—	1.9%
CSLLY Csl Ltd	$60.54B	—	—	—	0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section

Ownership

Institutional Holders Accumulating

Holders

193

% held: 95.5%
Net QoQ: +487.3K sh
Top holder: FMR LLC

Held Float

View

Held by Funds

Fund positions

150

View

Short & Settlement

Short Interest Rising

Shares short

6.1M

Days to cover: 10.4d
Change: +30.0K sh

View

Short Volume

Short vol %

65%

As of: Sep 9, 2026

Short Total

View

Fails to Deliver

FTD shares

495

Value: $22.8K
As of: Jul 17, 2026

View

Off-Exchange

Off-exchange %

50.2%

Week of: Aug 3, 2026

Off-exch Lit

View

Smart Money

Congressional Trades Sell

Member

Thomas R Carper

Amount: $1.0K–$15.0K
Traded: Oct 4, 2023

View

Financials

Net income (FY)

$-141.2M

EPS diluted: $-0.80

View

Filings

SEC Filings

Latest

8-K

Filed: Sep 8, 2026
This year: 14

View

Proposed Sales

Value

$1.7M

Shares: 35.5K
Filed: Jun 25, 2026

View

Exempt Offerings

Offering

$7.0M

Filed: Jan 10, 2022

View

Earnings & Events

Earnings Calls Upcoming

Next call

Sep 10, 2026

Last call: Jun 9, 2026

View

Investor Relations

Performance

	5D	20D	120D	MTD	YTD
GPCR	-12.5%	-20.9%	-20.5%	-10.2%	-40.7%
SPY	+0.1%	-1.1%	+15.3%	-0.6%	+11.8%
vs SPY	-12.6%	-19.9%	-35.8%	-9.6%	-52.5%

Key facts CIK 1888886 CUSIP 86366E106 13F (30d) 134 filings 134 filers Visit website Investor relations

GPCR · Structure Therapeutics Inc.

Price & Indicators

Up next

Metrics snapshot

Equibles Rating

Technicals

Key metrics

Versus peers

At a glance

Performance